GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sinovac Biotech Ltd (NAS:SVA) » Definitions » EPS without NRI

Sinovac Biotech (Sinovac Biotech) EPS without NRI

: $-4.07 (TTM As of Jun. 2023)
View and export this data going back to 2003. Start your Free Trial

Sinovac Biotech's earnings per share without non-recurring items for the six months ended in Jun. 2023 was $-0.32. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Jun. 2023 was $-4.07.

During the past 12 months, Sinovac Biotech's average earnings per share (NRI) Growth Rate was -112.40% per year. During the past 3 years, the average earnings per share (NRI) Growth Rate was 33.00% per year. During the past 5 years, the average earnings per share (NRI) Growth Rate was 82.00% per year. During the past 10 years, the average earnings per share (NRI) Growth Rate was 0.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Sinovac Biotech's EPS without NRI or its related term are showing as below:

SVA' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -138.7   Med: 17.2   Max: 480.4
Current: 33

During the past 13 years, Sinovac Biotech's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 480.40% per year. The lowest was -138.70% per year. And the median was 17.20% per year.

SVA's 3-Year EPS without NRI Growth Rate is not ranked
in the Biotechnology industry.
Industry Median: 4.45 vs SVA: 33.00

Sinovac Biotech's EPS (Diluted) for the six months ended in Jun. 2023 was $0.14. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was $-3.62.

Sinovac Biotech's EPS (Basic) for the six months ended in Jun. 2023 was $0.14. Its EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2023 was $-3.62.


Sinovac Biotech EPS without NRI Historical Data

The historical data trend for Sinovac Biotech's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sinovac Biotech Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EPS without NRI
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.38 0.44 1.03 74.28 1.03

Sinovac Biotech Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
EPS without NRI Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 44.80 29.48 3.41 -3.75 -0.32

Competitive Comparison

For the Biotechnology subindustry, Sinovac Biotech's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sinovac Biotech PE Ratio without NRI Distribution

For the Biotechnology industry and Healthcare sector, Sinovac Biotech's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Sinovac Biotech's PE Ratio without NRI falls into.



Sinovac Biotech EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-4.07

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sinovac Biotech  (NAS:SVA) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Sinovac Biotech EPS without NRI Related Terms

Thank you for viewing the detailed overview of Sinovac Biotech's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


Sinovac Biotech (Sinovac Biotech) Business Description

Traded in Other Exchanges
N/A
Address
No.39, Shangdi Xi Road, Haidan District, Beijing, CHN, 100085
Sinovac Biotech Ltd is a biopharmaceutical company. The company focuses on the research, development, manufacturing, and commercialization of vaccines for infectious diseases. Its product portfolio includes vaccines against hepatitis A and B, seasonal influenza, H5N1 pandemic influenza (avian flu), H1N1 influenza (swine flu), mumps, and canine rabies. The company also provides services for disease control and prevention, collaborating with the Chinese governments at the national, state, and local levels. It sells its vaccines in China, while also exploring growth opportunities in international markets.
Executives
Lily Wang director, 10 percent owner, officer: Chief Financial Officer 300 MURCHISON DR., MILLBRAE CA 94030
Ifg Investments Services Inc 10 percent owner PO BOX 822, CHARLESTOWN FEDERATION OF ST KITTS & NEVIS WEST INDIES P8 00000
Yin Weidong director, 10 percent owner, officer: President and CEO
Terry G Bowering director, 10 percent owner, officer: President, CEO 10 CEDAR MEADOW DRIVE REGINA A9 S4X 3J6

Sinovac Biotech (Sinovac Biotech) Headlines

From GuruFocus

SINOVAC COVID-19 Vaccine Is Conditionally Registered In South Africa

By Business Wire Business Wire 06-25-2022

SINOVAC to Showcase Products at CPHI Frankfurt

By Business Wire Business Wire 10-28-2022